Atranorin

Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC₅₀ values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions^{[1][2][3][4][5]}. In Vitro:Atranorin (0.01-10 μg/mL; 3 h) protects SH-SY5Y cells from H₂O₂-induced cytotoxicity^[1].
Atranorin (24 h) inhibits the expression of PD-L1 and TIM-3 in THP-1, KG-1 and Mono-Mac-1 cells, with the mechanism related to AKT pathway inhibition^[2].
Atranorin (0-10 μg/mL; 24-72 h) suppresses the migration and invasion of A549 cells. The mechanism involves the inhibition of AP-1, Wnt, STAT pathways and RhoGTPase activity^[3]. In Vivo:Atranorin (10 mg/kg; intraperitoneal injection; once every 3 days; 2 weeks) exhibits antitumor activity in a mouse lung cancer model^[3].
Atranorin (1-5%; topical application as an ointment; once daily; 3-21 days) promotes wound healing in a rat excisional wound model^[4].